Trial Profile
Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary) ; Tocilizumab (Primary) ; Tocilizumab (Primary)
- Indications COVID-19 pneumonia; COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms TOCIVID
- 08 Oct 2020 Status changed from recruiting to discontinued due to changed clinical conditions and too few patients available.
- 05 Apr 2020 Status changed from not yet recruiting to recruiting.
- 01 Apr 2020 Planned initiation date changed from 25 Mar 2020 to 4 Apr 2020.